Phaseline

Companies › Industrial Farmacéutica Cantabria

Industrial Farmacéutica Cantabria: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 1 Phase 3, 1 Phase 4, 1 Phase 2, 1 Phase 1; Immunology, Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Minoxidil
Sulfonylurea receptor 2, Kir6.2 opener
Ion channels, ABCC9Phase 3Androgenetic Alopecia; Central Centrifugal Cicatricial Alopecia (CCCA); Survivors of Childhood Cancer; Breast ReconstructionNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04207931MinoxidilPhase 4Central Centrifugal Cicatricial Alopecia (CCCA)ImmunologyNov 2026
NCT05888922MinoxidilPhase 3Androgenetic AlopeciaImmunologyNov 2026
NCT05778825MinoxidilPhase 2Survivors of Childhood CancerOncologyMar 2027
NCT07264790MinoxidilPhase 1Breast ReconstructionOncologySep 2027

Targets

Ion channels (1) ABCC9 (1)

Companies with the same targets

Xenon Pharmaceuticals Zhejiang Sunshine Mandi Pharmaceutical Praxis Precision Medicines HB BioTech Encoded Therapeutics Biohaven Therapeutics TLC Biopharmaceuticals Shenzhen Ausa Pharmed Grace Therapeutics LXO Ireland

Companies built like this

Zhejiang Sunshine Mandi Pharmaceutical VM Therapeutics Antengene Biologics Ganzhou Hemay Pharmaceutical Jiangsu vcare pharmaceutical technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.